PT1135166E - Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina - Google Patents

Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina

Info

Publication number
PT1135166E
PT1135166E PT99964009T PT99964009T PT1135166E PT 1135166 E PT1135166 E PT 1135166E PT 99964009 T PT99964009 T PT 99964009T PT 99964009 T PT99964009 T PT 99964009T PT 1135166 E PT1135166 E PT 1135166E
Authority
PT
Portugal
Prior art keywords
conjugates
nicotine
hapten
prevention
treatment
Prior art date
Application number
PT99964009T
Other languages
English (en)
Inventor
Ennifar Sofiane
Fattom Ali Ibrahim
Robert B Naso
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22747358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1135166(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Publication of PT1135166E publication Critical patent/PT1135166E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
PT99964009T 1998-12-01 1999-12-01 Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina PT1135166E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/201,800 US6232082B1 (en) 1998-12-01 1998-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction

Publications (1)

Publication Number Publication Date
PT1135166E true PT1135166E (pt) 2005-01-31

Family

ID=22747358

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99964009T PT1135166E (pt) 1998-12-01 1999-12-01 Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina

Country Status (26)

Country Link
US (7) US6232082B1 (pt)
EP (3) EP1512414A1 (pt)
JP (2) JP4971542B2 (pt)
KR (1) KR100656836B1 (pt)
CN (2) CN1220521C (pt)
AT (1) ATE279211T1 (pt)
AU (1) AU763001B2 (pt)
BR (1) BR9915852A (pt)
CA (1) CA2352765C (pt)
DE (1) DE69921178T2 (pt)
DK (1) DK1135166T3 (pt)
EA (1) EA004956B1 (pt)
ES (1) ES2229800T3 (pt)
HK (3) HK1042428B (pt)
HU (1) HUP0104365A3 (pt)
IL (2) IL143474A0 (pt)
ME (1) MEP34208A (pt)
MX (1) MXPA01005511A (pt)
NO (1) NO331998B1 (pt)
NZ (1) NZ512103A (pt)
PL (1) PL199253B1 (pt)
PT (1) PT1135166E (pt)
RS (1) RS51273B (pt)
TR (1) TR200102411T2 (pt)
WO (1) WO2000032239A1 (pt)
ZA (1) ZA200104477B (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
WO2002058635A2 (en) * 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20030148260A1 (en) * 2001-08-07 2003-08-07 Bernard Levin Method of diagnosing colorectal adenomas and cancer using proton maggnetic resonance spectroscopy
CA2477268A1 (en) * 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
EP1523334A2 (en) * 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-carrier conjugates and uses thereof
US20040115244A1 (en) * 2002-12-17 2004-06-17 Holgate Eric Jamison Methods and compositions for nicotine replacement therapy
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
WO2005040338A2 (en) * 2003-05-21 2005-05-06 The Scripps Research Institute Constrained alkaloid immunogens and antibodies and uses thereof
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006091796A2 (en) * 2005-02-22 2006-08-31 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
WO2007064478A2 (en) * 2005-11-28 2007-06-07 Nabi Biopharmaceuticals Method for making nicotine hapten
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US7547712B2 (en) * 2006-02-27 2009-06-16 Nabi Biopharmaceuticals Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
EP2007435B1 (en) 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
EP1849780A1 (en) 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
CN105770878A (zh) 2007-10-12 2016-07-20 麻省理工学院 疫苗纳米技术
CN101878228A (zh) * 2007-11-29 2010-11-03 赛托斯生物技术公司 尼古丁特异性人单克隆抗体
EP2065398A1 (en) * 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
WO2009149252A1 (en) * 2008-06-04 2009-12-10 Cornell University Vaccines for prevention and treatment of addiction
CA2727617A1 (en) * 2008-06-13 2009-12-17 Nabi Biopharmaceuticals Smoking cessation kit and method
US20110182918A1 (en) 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
CA2731494A1 (en) * 2008-08-08 2010-02-11 Novartis Ag Process for the preparation of nicotine-based haptens
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
AU2009325926B2 (en) 2008-12-09 2013-05-16 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
TW201109031A (en) * 2009-07-31 2011-03-16 Nabi Biopharmaceuticals Method and kit for treating nicotine addiction
KR101873179B1 (ko) * 2009-08-26 2018-06-29 셀렉타 바이오사이언시즈, 인크. Ｔ－세포 도움을 유도하는 조성물
WO2011031327A2 (en) * 2009-09-14 2011-03-17 The Scripps Research Institute Nicotine haptens, immunoconjugates and their uses
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
US9682133B2 (en) 2010-03-17 2017-06-20 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
AU2011258171B2 (en) 2010-05-26 2016-11-24 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
TWI455722B (zh) 2010-06-04 2014-10-11 Pfizer Vaccines Llc 用於預防或治療菸鹼成癮之共軛體
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US20140039063A1 (en) * 2011-01-04 2014-02-06 National Jewish Health Leukotrienes and asthma exacerbation risk
WO2012138774A2 (en) 2011-04-04 2012-10-11 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
WO2013130393A1 (en) 2012-02-28 2013-09-06 Cornell University Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
WO2013154744A1 (en) * 2012-04-13 2013-10-17 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
TWI600905B (zh) * 2012-09-21 2017-10-01 國立臺灣師範大學 聚合半抗原成為免疫原的技術方法
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
EP3145920B1 (en) * 2014-05-19 2019-09-18 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
CN104402992B (zh) * 2014-11-28 2018-09-18 杭州安旭科技有限公司 一种合成大麻抗原的合成方法及合成大麻抗原的应用
WO2016116477A1 (en) * 2015-01-20 2016-07-28 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CN106496309A (zh) * 2016-11-24 2017-03-15 北京开景基因技术有限公司 微球抗原及其制备方法以及抗可替宁抗体的制备方法
WO2018231706A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
MX2020001725A (es) 2017-08-15 2020-08-20 BliNK Biomedical Anticuerpos de fijacion a nicotina novedosos.
CN108362891B (zh) * 2017-12-27 2020-09-25 北京勤邦生物技术有限公司 一种泼尼松的磁免疫化学发光检测试剂盒及其应用
US11333372B2 (en) 2018-03-09 2022-05-17 Scot Matthew Duncan Energy recovery high efficiency dehumidification system
CN112512549A (zh) 2018-06-06 2021-03-16 安蒂多特疗法公司 改善循环和治疗心血管疾病的方法
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3888886A (en) * 1972-06-08 1975-06-10 Mobil Oil Corp Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst
US4045420A (en) 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US3888866A (en) 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US4053459A (en) 1975-09-24 1977-10-11 Hoffmann-La Roche Inc. Antibody specific to methaqualone and its metabolites
US4235864A (en) 1978-04-10 1980-11-25 Research Corporation Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites
US4376825A (en) 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
US4666837A (en) 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
SU1123704A1 (ru) 1983-04-08 1984-11-15 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов
EP0194158A3 (en) 1985-03-08 1988-02-24 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US4791067A (en) 1987-06-25 1988-12-13 Fisher Scientific Co. Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent
DE3884731D1 (de) 1987-10-09 1993-11-11 Ube Industries Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin.
US5268276A (en) 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
EP0363041A1 (en) 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine
GB9001694D0 (en) 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
CH678394A5 (pt) 1990-08-22 1991-09-13 Cerny Erich H
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5290784A (en) * 1991-07-18 1994-03-01 Yueqian Qu Aconitane derivatives used as a medication to treat addiction
US5233042A (en) 1991-12-16 1993-08-03 Biosite Diagnostics, Inc. Cocaine derivatives
US5283066A (en) 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
DE69332637T2 (de) 1993-03-04 2003-10-23 Matsushita Electric Ind Co Ltd Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
US5375414A (en) 1993-10-04 1994-12-27 Ford Motor Company Automotive engine exhaust aftertreatment system including hydrocarbon adsorber with internal engine purge flow control
WO1995027786A1 (en) 1994-04-08 1995-10-19 Immulogic Pharmaceutical Corporation Pharmaceutical formulations for treating japanese cedar pollen allergy
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US5876727A (en) 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO1996030049A2 (en) 1995-03-31 1996-10-03 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy
US5773003A (en) 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6455047B1 (en) * 1997-09-19 2002-09-24 Serex, Inc. Methods to improve immunogenicity of antigens and specificity of antibodies
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction

Also Published As

Publication number Publication date
MEP34208A (en) 2011-02-10
US20020004208A1 (en) 2002-01-10
HUP0104365A3 (en) 2002-05-28
JP2011079849A (ja) 2011-04-21
WO2000032239A1 (en) 2000-06-08
US6232082B1 (en) 2001-05-15
TR200102411T2 (tr) 2002-01-21
AU763001B2 (en) 2003-07-10
DK1135166T3 (da) 2005-02-14
JP4971542B2 (ja) 2012-07-11
US7247502B2 (en) 2007-07-24
ATE279211T1 (de) 2004-10-15
EP1135166A1 (en) 2001-09-26
CA2352765A1 (en) 2000-06-08
US20080026000A1 (en) 2008-01-31
CA2352765C (en) 2011-02-15
RS51273B (sr) 2010-12-31
EA004956B1 (ru) 2004-10-28
CN1768861A (zh) 2006-05-10
AU2033500A (en) 2000-06-19
WO2000032239A9 (en) 2002-08-22
US8026109B2 (en) 2011-09-27
HUP0104365A2 (hu) 2002-04-29
EP2324855A1 (en) 2011-05-25
PL199253B1 (pl) 2008-08-29
PL349012A1 (en) 2002-06-17
US20050136047A1 (en) 2005-06-23
US20110217320A1 (en) 2011-09-08
HK1042428B (zh) 2005-07-29
NO20012589D0 (no) 2001-05-25
YU39601A (sh) 2003-10-31
HK1042428A1 (en) 2002-08-16
BR9915852A (pt) 2004-06-29
NO20012589L (no) 2001-07-20
DE69921178T2 (de) 2005-11-17
CN1220521C (zh) 2005-09-28
IL143474A (en) 2006-06-11
EA200100610A1 (ru) 2002-04-25
US20110002957A1 (en) 2011-01-06
CN100586481C (zh) 2010-02-03
DE69921178D1 (de) 2004-11-18
NO331998B1 (no) 2012-05-21
EP1135166B1 (en) 2004-10-13
KR100656836B1 (ko) 2006-12-12
IL143474A0 (en) 2002-04-21
MXPA01005511A (es) 2004-08-19
ES2229800T3 (es) 2005-04-16
EP1512414A1 (en) 2005-03-09
KR20010090854A (ko) 2001-10-19
ZA200104477B (en) 2002-01-16
US7776620B2 (en) 2010-08-17
US20030165950A1 (en) 2003-09-04
NZ512103A (en) 2003-09-26
HK1043061A1 (en) 2002-09-06
US6773891B2 (en) 2004-08-10
US6518031B2 (en) 2003-02-11
HK1091415A1 (en) 2007-01-19
CN1329508A (zh) 2002-01-02
EP1135166B9 (en) 2005-02-02
HK1043061B (zh) 2006-07-07
JP2002531421A (ja) 2002-09-24

Similar Documents

Publication Publication Date Title
PT1135166E (pt) Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina
BR9711580A (pt) Conjugados hapteno-veìculo para uso em terapia contra uso indiscriminado de drogas e métodos para preparação destes
DE60234782D1 (de) Behandlungsverfahren mit liganden-immunogenkonjugaten
NO975555D0 (no) Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein
ATE109008T1 (de) T-zellen-epitope als träger für einen konjugierten impfstoff.
ATE512670T1 (de) Meningokokken-konjugat-impfung
ATE463261T1 (de) Meningokokken-konjugat-impfung
EP1329226A3 (en) Hapten-Carrier Conjugates for use in Drug Abuse Therapy
DK1329226T3 (da) Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug